Investors & News

Latest News

September 20, 2019
Stealth BioTherapeutics to Attend Upcoming Investor Conferences
September 03, 2019
Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
August 14, 2019
Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights
All News

Stock Quote (MITO)

Share

Why invest?

Our Company

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.

Our Programs

We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.

Our Pipeline

We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.

Latest Reports

March 14, 2019
6-K Report of Foreign Private Issuer
HTML
February 14, 2019
Stealth BioTherapeutics Prospectus
HTML
Reports

Latest Presentations

June 24, 2019
Investor Presentation June 2019
Presentations

Events

September 23, 2019
Ladenburg Thalmann Healthcare Conference
September 09, 2019
H.C. Wainwright Global Investment Conference
Financial Calendar
Media Relations

dna Communications
Lindsey Colegrove, 212-537-8771
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com